Actively Recruiting

Age: 0 - 85Years
All Genders
NCT02143986

Glycosylated Ferritin in Macrophagic Activation Syndromes

Led by Brugmann University Hospital · Updated on 2025-10-06

60

Participants Needed

1

Research Sites

865 weeks

Total Duration

On this page

Sponsors

B

Brugmann University Hospital

Lead Sponsor

U

Université Libre de Bruxelles

Collaborating Sponsor

AI-Summary

What this Trial Is About

In healthy subjects, from 50 to 80 % of the serum ferritin is glycosylated \[1, 2\] . A decrease in the percentage of ferritin glycosylation can be observed in inflammatory diseases, malignancies, infections, or liver disease but is rarely less than 20% \[3 , 4\] . Percentage of glycosylated ferritin below 20% have been described in patients with adult Still's disease and haemophagocytosis lymphohistiocytic syndromes (HLH). The glycosylated ferritin has been included in the diagnostic criteria for Still's disease in adults. A cut-off of less than 20 % has a sensitivity and specificity of 72 and 69 % respectively , and 35 and 94 % when combined with a total ferritin level greater than 5 times normal value. This parameter was also suggested to be a more specific marker to confirm a diagnosis of HLH than a high ferritin level ( \> 500μg / L). However, several limitations of this parameter were highlighted, some conditions making its interpretation difficult : particularly in cases of major hepatic cytolysis and severe sepsis (miliary tuberculosis, lymphoma and disease Adult Still). It is not always possible to distinguish severe sepsis, HLH syndrome and Still's disease. A fine analysis of various glycoforms components of ferritin could be used to distinguish different subgroups of patients. Few data are available on the mechanism of secretion and glycosylation of ferritin, but the investigators assume that the glycosylation patterns of ferritin may vary between different disease states and reflect distinct underlying pathophysiological mechanisms.

CONDITIONS

Official Title

Glycosylated Ferritin in Macrophagic Activation Syndromes

Who Can Participate

Age: 0 - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Suspicion of sepsis, macrophagic activation syndrome, Still's disease, or hyperferritinemia (malignant disease, hepatic cytolysis)
Not Eligible

You will not qualify if you...

  • Normal ferritin level

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Brugmann University Hospital

Brussels, Belgium, 1020

Actively Recruiting

Loading map...

Research Team

F

Francis Corazza, MD, PhD

CONTACT

F

France Debaugnies, Pharm

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here